Submitted:
11 February 2025
Posted:
13 February 2025
You are already at the latest version
Abstract
Cystic fibrosis (CF) patients experience higher risks of colorectal cancer, but pathogenesis is unclear. In the general population, polyketide synthase-positive (pks+) E. coli is impli-cated in intestinal carcinogenesis via production of colibactin, however relevance in CF is unknown. We investigated pks+ E. coli prevalence in CF at baseline and longitudinally, performing PCR on stool DNA extracts. Potential associations between pks+ E. coli and gastrointestinal inflammation or microbiome dynamics were analysed using faecal calprotectin and 16SrRNA gene taxonomic data. At baseline, no difference in pks+ E. coli carriage was identified between CF and healthy controls, 21/55(38%) vs 26/55(47%), p=0.32. Pks+ E. coli was not associated with significant differences in mean (SD) calpro-tectin concentration (124(154) vs 158(268) mg/kg; p=0.60), microbial richness (159(76.5) vs 147(70.4); p=0.50) or Shannon diversity index (2.78(0.77) vs 2.65(0.74); p=0.50) in CF. Lon-gitudinally, subjects demonstrated intra-individual variation in pks+ E. coli presence, however no significant difference in overall prevalence was observed. Thus, intesti-nal pks+ E. coli prevalence was not different between CF and healthy controls, nor associ-ated with differences in gut microbial profile or inflammation. Investigating effects of re-peat exposure on risk profile and analysis of older CF cohorts is necessary to identify if associations with colorectal cancer exist.
Keywords:
1. Introduction
2. Materials and Methods
Study Design
DNA Extraction and Sequencing
Faecal Calprotectin
Identification of E. coli and pks-Producing E. coli
Statistical Analysis
3. Results
Demographics
| 1A: Baseline | Cystic fibrosis patients | Healthy controls | P-value | 95% CI | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Number of participants | 55 | 55 | ||||||||
| Male sex, n (%) | 26 (47%) | 26 (47%) | 1 | |||||||
| Mean age in years (SD) | 7.66 (5.1) | 7.78 (5.0) | 0.17 | (-0.29,0.05) | ||||||
| Exocrine pancreatic status | ||||||||||
| Pancreatic sufficient (%) | 7 (13%) | |||||||||
| Pancreatic insufficient (%) | 48 (87%) | |||||||||
| Anthropometrics | ||||||||||
| Mean weight z-scores (SD) | -0.24 (1.23) | |||||||||
| Mean height z-scores (SD) | 0.00 (1.01) | |||||||||
| Mean BMI z-scores (SD) | 0.39 (0.71) | |||||||||
| 1B: Longitudinal | Cystic fibrosis patients | |||||||||
| Number of participants | 23 | |||||||||
| Male sex, n (%) | 10 (38%) | |||||||||
| Mean age in years (SD) | T1 | T2 | T3 | |||||||
| 7.0 (4.2) | 7.8 (4.2) | 8.8 (3.9) | ||||||||
| Exocrine pancreatic status | ||||||||||
| Pancreatic sufficient (%) | 4 (17%) | |||||||||
| Pancreatic insufficient (%) | 19 (83%) | |||||||||
Microbiome Diversity and Inflammation

Prevalence of pks+ E. coli at Baseline
Prevalence of pks+ E. coli in Longitudinal Analysis of the CF Cohort
4. Discussion
Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Coffey, M.J., et al. Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. Sci. Rep. 9, 18593 (2019). [CrossRef]
- Manor, O., et al. Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis. Sci. Rep. 6, 22493 (2016). [CrossRef]
- Burke, D.G., et al. The altered gut microbiota in adults with cystic fibrosis. BMC Microbiol. 17, 58 (2017). [CrossRef]
- Tam, R.Y., van Dorst, J.M., McKay, I., Coffey, M. & Ooi, C.Y. Intestinal Inflammation and Alterations in the Gut Microbiota in Cystic Fibrosis: A Review of the Current Evidence, Pathophysiology and Future Directions. J. Clin. Med. 11, 649 (2022). [CrossRef]
- Kristensen, M., et al. Development of the gut microbiota in early life: The impact of cystic fibrosis and antibiotic treatment. J. Cyst. Fibros. 19, 553-561 (2020). [CrossRef]
- Yamada, A., et al. Risk of gastrointestinal cancers in patients with cystic fibrosis: a systematic review and meta-analysis. Lancet Oncol. 19, 758-767 (2018). [CrossRef]
- Maisonneuve, P., Marshall, B.C., Knapp, E.A. & Lowenfels, A.B. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J. Natl. Cancer Inst. 105, 122-129 (2013). [CrossRef]
- Yatsunenko, T., et al. Human gut microbiome viewed across age and geography. Nature 486, 222-227 (2012). [CrossRef]
- Matamouros, S., et al. Adaptation of commensal proliferating Escherichia coli to the intestinal tract of young children with cystic fibrosis. Proc. Natl. Acad. Sci. U.S.A. 115, 1605-1610 (2018). [CrossRef]
- Pakbin, B., Brück, W.M. & Rossen, J.W.A. Virulence Factors of Enteric Pathogenic Escherichia coli: A Review. Int. J. Mol. Sci. 22, 9922 (2021). [CrossRef]
- Faïs, T., Delmas, J., Barnich, N., Bonnet, R. & Dalmasso, G. Colibactin: More Than a New Bacterial Toxin. Toxins (Basel) 10, 151 (2018). [CrossRef]
- Dalmasso, G., Cougnoux, A., Delmas, J., Darfeuille-Michaud, A. & Bonnet, R. The bacterial genotoxin colibactin promotes colon tumor growth by modifying the tumor microenvironment. Gut Microbes 5, 675-680 (2014). [CrossRef]
- Arthur, J.C., et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 5, 4724 (2014). [CrossRef]
- Dougherty, M.W. & Jobin, C. Shining a Light on Colibactin Biology. Toxins (Basel) 13, 346 (2021). [CrossRef]
- Eklöf, V., et al. Cancer-associated fecal microbial markers in colorectal cancer detection. Int. J. Cancer 141, 2528-2536 (2017). [CrossRef]
- Coffey, M.J., et al. Evaluating the Alimentary and Respiratory Tracts in Health and disease (EARTH) research programme: a protocol for prospective, longitudinal, controlled, observational studies in children with chronic disease at an Australian tertiary paediatric hospital. BMJ Open 10, e033916 (2020). [CrossRef]
- Nielsen, S., et al. Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. Sci. Rep. 6, 24857 (2016). [CrossRef]
- Garnett, E., et al. Validation of the newly FDA-approved Buhlmann fCal Turbo assay for measurement of fecal calprotectin in a pediatric population. Pract. Lab. Med. 22, e00178 (2020). [CrossRef]
- Arthur, J.C., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338, 120-123 (2012). [CrossRef]
- Tantawiwat, S., Tansuphasiri, U., Wongwit, W., Wongchotigul, V. & Kitayaporn, D. Development of multiplex PCR for the detection of total coliform bacteria for Escherichia coli and Clostridium perfringens in drinking water. Southeast Asian J. Trop. Med. Public Health. 36, 162-169 (2005).
- Anderson, M.J. A new method for non-parametric multivariate analysis of variance. Austral Ecol. 26, 32-46 (2001).
- Hadley, W. ggplot2: Elegant Graphics for Data Analysis, (Springer-Verlag New York, 2016).
- Bruzzese, E., et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment. Pharmacol. Ther. 20, 813-819 (2004). [CrossRef]
- Ai, D., et al. Identifying Gut Microbiota Associated With Colorectal Cancer Using a Zero-Inflated Lognormal Model. Front. Microbiol. 10, 826 (2019). [CrossRef]
- Oliero, M., et al. Prevalence of pks + bacteria and enterotoxigenic Bacteroides fragilis in patients with colorectal cancer. Gut Pathog. 14, 51 (2022). [CrossRef]
- Luo, C., et al. Genetic and Functional Analysis of the pks Gene in Clinical Klebsiella pneumoniae Isolates. Microbiol. Spectr. 11, e00174-00123 (2023). [CrossRef]
- Clooney, A.G., et al. Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. Gut 70, 499-510 (2021). [CrossRef]
- Ooi, C.Y., et al. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. Sci. Rep. 8, 17834 (2018). [CrossRef]
- McKay, I., et al. Diet and the gut-lung axis in cystic fibrosis – direct & indirect links. Gut Microbes 15, 2156254 (2023). [CrossRef]
- Arima, K., et al. Western-Style Diet, pks Island-Carrying Escherichia coli, and Colorectal Cancer: Analyses From Two Large Prospective Cohort Studies. Gastroenterology 163, 862-874 (2022). [CrossRef]
| 2A | ||||
| Diagnosis | ||||
| clbB status | Cystic fibrosis | Healthy controls | Total | |
| Positive | 21 | 26 | 47 | |
| Negative | 34 | 29 | 63 | |
| Total | 55 | 55 | 110 | |
| 2B | Mean (SD) | p-value | ||
| Calprotectin (mg/kg) | ||||
| clbB positive | 124 (154) | 0.6 | ||
| clbB negative | 158 (268) | |||
| Shannon diversity (Shannon Index (H)) | ||||
| clbB positive | 2.78 (0.77) | 0.5 | ||
| clbB negative | 2.65 (0.74) | |||
| Microbial richness | ||||
| clbB positive | 159 (76.5) | 0.5 | ||
| clbB negative | 147 (70.4) | |||
| P - value | Standard Error | Estimate | T-value | |||
|---|---|---|---|---|---|---|
| Richness | ||||||
| Timepoint 2 | 0.9 | 10.8 | 1.79 | 0.16 | ||
| Timepoint 3 | 0.135 | 11.1 | 16.9 | 1.52 | ||
| Sex | 0.5 | 12.4 | 8.17 | 0.66 | ||
| Age | 0.0589 | 1.52 | 3.04 | 2.00 | ||
| Variance of intercepts | 412.9 | 20.3 | ||||
| Variance of residuals | 1330.1 | 36.5 | ||||
| Shannon Diversity | ||||||
| Timepoint 2 | 0.178 | 0.16 | -0.22 | -1.37 | ||
| Timepoint 3 | 0.5 | 0.17 | 0.10 | 0.61 | ||
| Sex | 0.2 | 0.21 | 0.27 | 1.29 | ||
| Age | 0.6 | 0.025 | 0.013 | 0.51 | ||
| Variance of intercepts | 0.154 | 0.0393 | ||||
| Variance of residuals | 0.295 | 0.543 | ||||
| Chao1 | ||||||
| Timepoint 2 | 0.9 | 14.5 | 0.49 | 0.034 | ||
| Timepoint 3 | 0.2 | 14.8 | 17.7 | 1.20 | ||
| Sex | 0.4 | 14.2 | 10.4 | 0.73 | ||
| Age | 0.0306* | 1.75 | 4.07 | 2.32 | ||
| Variance of intercepts | 344.9 | 18.6 | ||||
| Variance of residuals | 2381.7 | 48.8 | ||||
| Timepoint 1 | Timepoint 2 | Timepoint 3 | |
|---|---|---|---|
| CF1 | + | ||
| CF2 | + | ||
| CF3 | - | - | - |
| CF4 | + | + | + |
| CF5 | + | - | + |
| CF6 | - | - | - |
| CF7 | - | + | - |
| CF8 | - | - | + |
| CF9 | |||
| CF10 | - | ||
| CF11 | - | - | + |
| CF12 | + | + | + |
| CF13 | + | - | + |
| CF14 | - | + | - |
| CF15 | - | + | |
| CF16 | + | + | |
| CF17 | - | - | + |
| CF18 | + | - | + |
| CF19 | + | + | + |
| CF20 | - | + | - |
| CF21 | + | - | |
| CF22 | + | - | + |
| CF23 | - | - | + |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).